Market Announcement

16 July 2026

4DMedical Limited (ASX: 4DX) – Trading Halt

Trading in the securities of 4DMedical Limited ('4DX') will be halted at the request of 4DX, pending the release of an announcement by 4DX.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 17 July 2026; or
- the release of the announcement to the market.

4DX's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

16 July 2026

Melissa Kostopoulos
ASX Limited
Level 50, South Tower
525 Collins Street
MELBOURNE VIC 3000

By email: Melissa.Kostopoulos@asx.com.au; TradingHaltsMelbourne@asx.com.au

Dear Melissa,

Request for trading halt: 4DMedical Limited (ASX: 4DX)

4DMedical Limited (**Company**) requests a trading halt to be applied to the Company's securities (ASX: 4DX) quoted on the Australian Securities Exchange (**ASX**), in accordance with ASX Listing Rule 17.1, from the commencement of trading today.

The trading halt is requested pending an announcement by the Company to the market regarding the potential implications for the Company in relation to a bill being proposed in US Congress (**Stated Purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the Stated Purpose above.

2. The Company requests that the trading halt remain in place until the earlier of commencement of normal trading on Friday, 17 July 2026 or when the announcement regarding the Stated Purpose is released to the market.

3. The Company expects to make the announcement regarding the Stated Purpose to the market before the commencement of normal trading on Friday, 17 July 2026.

4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

This request has been authorised by the Managing Director & CEO of 4DMedical Limited.

Please contact me if you require any further information concerning this matter.

Sincerely,

4DMedical Limited
Hamish George
Company Secretary